Physician profile
Anny Eusebio
NPI 1841323391
$5,115.10
in general payments reported to CMS, 2019-2025
23 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $428 · 2023: $1,269 · 2024: $1,721 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,139 · Travel and Lodging: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,138.51 |
| Travel and Lodging | $367.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $924.18 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $887.95 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $728.59 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $662.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $505.24 | 2022-2024 | Farxiga, Lokelma, Wainua |
| Novo Nordisk INC | $271.76 | 2023-2025 | Wegovy |
| Bridgebio Pharma, INC. | $226.13 | 2025 | Attruby |
| Abbott Laboratories | $203.05 | 2021-2025 | Aveir |
| Amgen INC. | $160.94 | 2022-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $122.99 | 2024 | Inpefa |
| Pfizer INC. | $75.78 | 2023-2025 | |
| Boston Scientific Corporation | $53.79 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.84 | 2025 | |
| Glaxosmithkline, LLC. | $41.72 | 2025 | Arexvy, Shingrix |
| W. L. Gore & Associates, INC. | $40.63 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $34.09 | 2025 | Telepatch Cardiac Monitor |
| Abiomed | $25.48 | 2025 | |
| Impulse Dynamics (USA) INC. | $24.39 | 2024 | Optimizer |
| Chiesi USA, INC. | $23.48 | 2025 | Juxtapid |
| Kiniksa Pharmaceuticals International, Plc | $17.00 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $16.43 | 2023 | Arcalyst |
| G Medical Diagnostic Services, INC. | $13.75 | 2022 | |
| Amarin Pharma, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anny Eusebio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.